(Q38109244)

29 August 2017

Novel routes to bipolar disorder drug discovery (English)

1 reference

29 August 2017

1 reference

1 reference

Pierre de Maricourt

2

0 references

Philip Gorwood

object named as

Philip Gorwood

series ordinal

3

0 references

author name string

Nicolas Hoertel

series ordinal

1

1 reference

PubMed ID

23706065

29 August 2017

language of work or name

English

0 references

publication date

27 May 2013

1 reference

Expert Opinion on Drug Discovery

29 August 2017

1 reference

29 August 2017

8

1 reference

29 August 2017

8

1 reference

29 August 2017

907-918

1 reference

Clinical practice. Bipolar disorder--a focus on depression

29 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Subthreshold bipolar disorder in a U.S. national representative sample: prevalence, correlates and perspectives for psychiatric nosography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Prevalence of subthreshold hypomania and impact on internal validity of RCTs for major depressive disorder: results from a national epidemiological sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Circadian genes, rhythms and the biology of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Mania-like behavior induced by disruption of CLOCK

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Neuronal pathology in the hippocampal area of patients with bipolar disorder: a study with proton magnetic resonance spectroscopic imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Challenges in drug target discovery in bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Lithium and valproic acid: parallels and contrasts in diverse signaling contexts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Glycogen synthase kinase 3: more than a namesake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

New therapeutic targets for mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Novel drugs and therapeutic targets for severe mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders--focus on magnetic resonance spectroscopy (MRS) studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Progressive gray matter loss in patients with bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Brain-derived neurotrophic factor serum levels before and after treatment for acute mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Meta-analysis of genetic association studies on bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Selective DNA methylation of BDNF promoter in bipolar disorder: differences among patients with BDI and BDII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Epigenetic regulation in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Valproic acid and chromatin remodeling in schizophrenia and bipolar disorder: preliminary results from a clinical population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

The language of covalent histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

The relationship between free and total calcium concentrations in the matrix of liver and brain mitochondria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Endoplasmic reticulum chaperones GRP78 and calreticulin prevent oxidative stress, Ca2+ disturbances, and cell death in renal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

An open-label trial of riluzole in patients with treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Pramipexole for bipolar II depression: a placebo-controlled proof of concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Effect of antioxidant diets on mitochondrial gene expression in rat brain during aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Coenzyme Q10 effects on creatine kinase activity and mood in geriatric bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Insulin dysfunction and allostatic load in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Purinergic signalling in neuron-glia interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Role of melatonin in mood disorders and the antidepressant effects of agomelatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Generalizability of clinical trial results for bipolar disorder to community samples: findings from the National Epidemiologic Survey on Alcohol and Related Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Generalizability of clinical trial results for generalized anxiety disorder to community samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Are subjects in treatment trials of panic disorder representative of patients in routine clinical practice? Results from a national sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Accounting for population stratification in practice: a comparison of the main strategies dedicated to genome-wide association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Animal models relevant to schizophrenia and autism: validity and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Modelling schizophrenia using human induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

GSK-3: tricks of the trade for a multi-tasking kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.804057

10.1517/17460441.2013.804057

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

23706065